Skip to main content
  • an Accelerating Medicines Partnership® (AMP®) program
Register or Renew Workbench

NEI Main Menu

  • Register or Renew Workbench
  • About
      • About AMP PD
      • AMP PD Use Cases
      • Contact Us
      • Glossary
      • Who we are
      • Contributor Spotlights
  • News & Updates
      • News & Updates
      • Release Updates
      • AMP PD Research Plan
      • News & Articles Archive
      • Publications Archive
  • Data
      • Data
      • Harmonized Data
        • Summary Data Dashboard
        • Whole Genome Data
        • Transcriptomics Data
        • Targeted Proteomics Data
        • Clinical Assessment Data
      • Federated Data
        • GP2 Cohort Dashboard
        • Genomic Data
  • Cohorts
      • Cohorts
      • Unified Cohorts
        • BioFIND
        • HBS
        • LBD
        • LCC
        • PDBP
        • PPMI
        • STEADY-PD3
        • SURE-PD3
      • Federated Cohorts
        • GP2
  • Tools
      • Terra Platform
      • SmartConverter Data Curation
      • Visualization Tools & Resources
  • Researchers
      • Knowledge Platform Governance
      • Register for AMP PD
      • Data Use Agreement
  • Portal Resources
      • How To & References
      • AMP PD Training Videos
      • Cloud Cost Guidelines
      • Cloud Architecture
      • Computing Guidelines
  • FAQs
Register or Renew Workbench
  • Home
  • /
  • < Back To Unified Cohorts
  • /
  • PDBP

PDBP

  • Study Overview
  • Goals and Objectives
  • Study Specific Data Contribution
  • Inclusion and Exclusion Criteria
  • Study Protocol and Details

PDBP Study Overview

The National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP) was developed to accelerate the discovery of promising new diagnostic and progression biomarkers for Parkinson's Disease.

The Parkinson's Disease Biomarkers Program (PDBP) is made up of researchers, patients, family members, and healthcare professionals who are dedicated to accelerating the pace of biomarkers research.

The PDBP supports basic, translational and clinical research through hypothesis testing, target and pathway discovery, biomarker development, and disease modeling through broadly sharing data and biospecimens developed under this program.

Total Participants (Cohort records that met the AMP PD minimum clinical data criteria):

1,604

AMP PD Designation:

Data from the PDBP cohort is designated with the prefix “PD”  in the AMP PD Portal.  PDBP data in the AMP PD portal includes: Demographics, family history, medication history, UPSIT, MDS-UPDRS, MoCA, WGS, blood transcriptomics

Additional Study Information:

PDBP

PDBP Data Management Resource (DMR)

PDBP Goals and Objectives

To overcome current roadblocks to better clinical trial design through improved assessment of PD progression across the disease spectrum, the PDBP will focus on building resources and supporting research that promotes the discovery of PD diagnostic and progression biomarkers.

In considering the landscape of current PD biomarker efforts across institutional, government and non-government agencies, the PDBP will facilitate research and the development of resources that bridge the gap between small pilot biomarker studies and validation studies of well replicated biomarker candidates.

In bridging this gap, the PDBP will support new and existing cohort studies that collect standardized longitudinal clinical data and biospecimens across all stages of PD, with the goal of coalescing this data into a single database that enables data to be shared broadly with the research community.

The PDBP will also support the development of analytical tools that will promote innovation around biomarker discovery. By recognizing the contribution of current biomarker studies and providing the resources necessary to successfully replicate promising biomarker candidates and promote innovative analytical solutions, the PDBP through its Data Management Resource, will work to unite and leverage these efforts to accelerate biomarker discovery for Parkinson's disease.
 

Study Specific Data Contribution

All variables and associated data provided by PDBP have been harmonized across the contributing cohorts.

PDBP Inclusion and Exclusion Criteria

All Participants - Inclusion
All Participants - Exclusion
Case Specific Criteria
Control Specific Criteria

All Participants - Inclusion

  1. Male or Female aged 21 years or older at screening
  2. Able to cooperate with consent procedures (or has appropriate surrogate as defined and approved per local IRB)
  3. Able to participate in study activities including all required clinical assessments and biological donations
  4. Participation would not lead to hardship or adverse health or mental health conditions
     

All Participants - Exclusion

  1. Condition that preclude the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or coagulopathy or thrombocytopenia
  2. Current treatment with anti-coagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture
  3. Has a history of neuroleptic use or exposure
  4. Has a history of schizophrenia
  5. Otherwise unable to participate in biological specimen collection due to a medical condition or medication status (other than items listed above)
  6. Otherwise unable to participate in clinical assessments due to a medical condition or medication status (other than items listed above)
  7. Unable to participate in consent procedures
  8. Use of investigational drugs or devices within 60 days prior to baseline visit (dietary supplements such as Coenzyme Q10, for example, are not exclusionary)
     

Case Specific Criteria

Inclusion:

  1. Clinically diagnosed with Parkinson's Disease

Exclusion:

  1. Clinical Diagnosis uncertain at time of enrollment
     

Control Specific Criteria

Inclusion:

  1. None

Exclusion:

  1. Has a current or clinically significant neurological disorder in the opinion of the investigator
  2. Family history of Neurodegenerative disease in a first degree relative or second degree blood relative
     

For further information regarding PDBP inclusion/exclusion criteria, please contact: PDBP-OPS@mail.nih.gov

PDBP Study Protocol

PDBP Projects & Protocols

PDBP Clinical Research Forms

ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.

Footer Links

  • Contact us
  • Policy & Governance
  • Privacy Statement
  • Disclaimer
  • Site Map
  • Accessibility Policy
  • Reuse & Copyright
  • Glossary